What is Sativex and what is it used for?
Sativex is actually a tincture-based extract from the cannabis plant. Sativex, also known as nabiximols, is a cannabis-based oral spray “medicine for the treatment of spasticity due to multiple sclerosis which is also in development in cancer pain” according to GW Pharmaceuticals. They are in “Phase III clinical development for the treatment of cancer pain”. It is a mouth spray that delivers 1:1 CBD to THC ratio with 2.7 mg of THC and 2.5 mg of CBD. The equal dosage was manufactured that way so it be standardized. People who consume Sativex will experience a “high” because of the THC content.
Where is Sativex legal in the world?
Sativex has been launched in 15 countries and is in the process of introducing Sativex into more new countries. Sativex is an approved pharmaceutical in 27 different countries. This is quite ironic, at least in the United States, where cannabis is still listed as Schedule 1 drug under the Controlled Substances Act. These Schedule 1 drugs qualify as having no medicinal value and highly addictive.
Anway, GW Pharmaceuticals has six different licensing agreements all over the world shown below:
- Sativex – with Bayer HealthCare in the UK and Canada
- Almirall in Europe (excluding the UK) and Mexico
- Otsuka Pharmaceutical Co. Ltd in the United States
- Novartis in the Middle East (excluding Israel), Africa, and Asia (excluding China and Japan)
- Ipsen for Latin America;
- Neopharm in Israel.
Who is GW Pharmaceuticals?
GW Pharmaceuticals is a pharmaceutical company started in 1998. They are a multinational company with stock trading on the NASDAQ (ticker symbol: GWPH) and on the London Stock Exchange. They claim to have a product portfolio based on cannabinoids found in cannabis. This cannabinoid-based product mix includes Sativex Oromucosal Spray and Epidiolex for childhood epilepsy.